GYNECOLOGICAL CANCER DRUGS MARKET ANALYSIS

Gynecological Cancer Drugs Market, By Therapeutic Modality (Chemotherapy, Targeted Therapy, and Hormonal Therapy), By Indication (Uterine Cancer, Ovarian Cancer, Vaginal & Vulvar Cancer, and Cervical Cancer), and By Region - Size, Share, Outlook, and Opportunity Analysis, 2022-2028

To Be Published : Dec 2024
Code : CMI1744
Formats :
Excel and PDF
Industry : Pharmaceutical

Market News

For instance, Dr Reddy’s Laboratories based in India, in May 2017, received US Food and Drug Administration approval to launch Doxorubicin Hydrochloride Liposome injection in the U.S. market. This Doxorubicin Hydrochloride Liposome is a therapeutic equivalent generic version of Doxil, which is a chemotherapy drug used in the treatment of certain cancer such as ovarian cancer, AIDS-related Kaposi's sarcoma, and multiple myeloma.

Furthermore, in 2017, US FDA also approved Zejula (niraparib), which is targeted therapy drug for women with some types of ovarian, fallopian tube, or peritoneal cancers. It is also approved for women with relapsed cancer after chemotherapy. American Cancer Society, as of March 2018 has funded around 22 grants for cervical cancer, which accounted for around US$ 9.3 million. The funding value is offered to a single or group of research, which includes a specific type of a cancer or area of cancer.